Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN)

NCT02125318 is registered in ClinicalTrials.gov with Galena Biopharma, Inc. as lead sponsor.

NCT NCT02125318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02125318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN)
Lead sponsor
Galena Biopharma, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2014
Completion date
May 31, 2016
Enrollment
18 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

myeloproliferative neoplasms, thrombocytosis